Accessibility StatementSkip Navigation BOSTON, Nov. 11, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, to launch and co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDMâ"¢ on Complete Genomics' DNBSEQ-T1+ sequencing platform. The companies aim to broaden access to precision oncology testing by offering the best-in-class liquid biopsy and solid tu ...

Core Insights - SOPHiA GENETICS and Element Biosciences announced a partnership to integrate sequencing and AI analytics, aiming to enhance genomic workflows and support precision medicine research [1][2][4] Company Overview - SOPHiA GENETICS is a leader in AI-driven precision medicine, focusing on expanding access to data-driven healthcare through its SOPHiA DDM™ platform [8] - Element Biosciences is transforming scientific discovery with advanced technologies that enhance the pace and accessibility of genomics [9] Partnership Details - The collaboration combines SOPHiA DDM™ with Element's AVITI24™ 5D multiomic and AVITI sequencing systems, creating a streamlined end-to-end workflow for next-generation sequencing (NGS) [2] - This integration is expected to provide speed, scalability, and flexibility, allowing clinical researchers to derive actionable insights from NGS data efficiently [2][4] Expected Impact - The partnership aims to democratize access to genomic research, enabling healthcare organizations of all sizes to adopt innovative, AI-driven technologies [4] - The collaboration is anticipated to enhance the accuracy and consistency of genomic testing, ultimately accelerating the delivery of precision medicine to more patients [3][4]

Company Overview The AI Platform for Precision Medicine November 4, 2025 Cautionary notices This presentation contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, products and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking ...

Company Overview - SOPHiA GENETICS' Ai platform SOPHiA DDM™ is used by over 800 healthcare institutions globally to analyze complex health data for cancer and rare disorders[7] - The platform analyzes over 350,000 patients annually and has analyzed over 2 million profiles since its inception[8, 21] - The company has invested over $450 million since its inception in its Ai platform[21, 57] Market Trends - The incidence of cancer and rare disorders is increasing worldwide, driving demand for targeted therapies[13] - Healthcare data is rapidly expanding, with 30% of all data generated globally being healthcare-related[16] - The Total Addressable Market (TAM) for Liquid Biopsy is estimated to be over $5 billion[56] Financial Performance - SOPHiA GENETICS' revenue for 2024 was $65.2 million[60] - The company projects revenue between $72 million and $76 million for 2025, representing a year-over-year growth of approximately 10% to 17%[60, 63] - Adjusted EBITDA loss is projected to be between $35 million and $39 million in 2025, compared to $40.2 million in 2024[63] - The company's adjusted gross margin was 72.8% in 2024 and is expected to expand slightly in 2025[63]

Financial Performance - SOPHiA GENETICS reported Q2 2025 revenue of $18.3 million, reflecting a 16% year-over-year growth [7][12] - Adjusted gross margin improved to 74.4%, up 120 basis points from the previous year [3][12] - The company experienced a net loss of $22.4 million, which is a 48% increase year-over-year [7][12] Business Highlights - The company signed 35 new core genomics customers in Q2 2025, a significant increase from 19 new customers in Q2 2024 [3][8] - A major multi-year AI breast cancer partnership was established with AstraZeneca, marking the largest contract in the company's history [3][12] - The total number of core genomics customers reached 490 as of June 30, 2025, up from 457 at the end of Q2 2024 [8] Operational Efficiency - Cash burn improved by 35% year-over-year, totaling $8.7 million for the quarter [3][7] - The company performed 95,000 analyses on SOPHiA DDMTM, representing a 9% year-over-year volume growth [8] - The partnership with Dasa, the largest medical diagnostics company in Latin America, was expanded to include additional applications [8] Future Outlook - SOPHiA GENETICS reaffirmed its full-year revenue guidance of $72 million to $76 million, indicating a growth of approximately 10% to 17% compared to FY 2024 [12] - The company expects to approach adjusted EBITDA breakeven by the end of 2026 and achieve positive adjusted EBITDA in the second half of 2027 [12]

Company Overview and Platform - SOPHiA GENETICS's AI platform SOPHiA DDM is used by over 800 healthcare institutions globally [7] - The platform analyzes over 350,000 patients per year and has analyzed over 2 million profiles since inception [8, 21] - The company has invested over $450 million since inception in its AI platform [21] Market Trends and Data Analysis - Healthcare data accounts for 30% of all data generated globally [17] - In 2024, SOPHiA DDM performed over 350,000 genomic analyses, with over 93,000 in Q1 2025 [33] - Total data processed on SOPHiA DDM has seen compounded growth of over 50% since 2021 [46] Financial Performance and Outlook - SOPHiA GENETICS' revenue for 2024 was $65.2 million [68] - The company projects revenue between $72 million and $76 million for 2025, representing approximately 10% to 17% year-over-year growth [71] - Adjusted gross margin was 72.8% in 2024 and is expected to expand slightly in 2025 [71] - The company had a cash balance of $68.5 million as of Q1 2025 [76]

Core Insights - SOPHiA GENETICS reported a strong start to 2025 with a year-over-year revenue growth of 13%, or 15% on a constant currency basis, driven by new business signed in 2024 [3][7] - The company achieved a record adjusted gross margin of 75.7%, up 520 basis points year-over-year, indicating effective cost management and operational efficiency [3][7] - The company continues to focus on long-term growth prospects, particularly in the U.S. market, where revenue from core genomics customers grew over 30% [3][13] Financial Performance - Revenue for Q1 2025 was $17.8 million, reflecting a 13% increase from $15.8 million in Q1 2024 [7][35] - Adjusted EBITDA loss improved by 24% year-over-year to $9.8 million, demonstrating progress towards profitability [7][33] - The company reaffirms its full-year revenue guidance of $72 million to $76 million, representing a growth of approximately 10% to 17% compared to FY 2024 [7][13] Business Highlights - SOPHiA DDM™ platform performed 93,000 analyses in Q1 2025, marking an 11% year-over-year volume growth [8] - The company onboarded 33 new core genomics customers in Q1 2025, up from an average of 23 customers per quarter in 2024 [8] - Significant demand for new applications, including the Liquid Biopsy application MSK-ACCESS®, has led to a healthy pipeline of over 60 identified opportunities [9][10] Market Expansion - The company expanded its collaboration with AstraZeneca to accelerate the deployment of MSK-ACCESS® globally, now involving 30 sponsored institutions [8] - New customers were signed across various geographies, including notable institutions in Belgium, Canada, and Malaysia [8][9] - The U.S. market continues to show strong business growth, with a focus on operational excellence and sustainable growth strategies [10][11]